The drug Remdesivir, developed by US-based Geelya Inc., was seen as an effective new drug to curb pneumonia in Wuhan after successfully saving the first confirmed patient in the United States.
Immediately after the news broke, the wuhan institute of viruses of the chinese academy of sciences announced on wednesday (5) that it had filed a patent for the "application of coronavirus "(which could treat wuhan pneumonia). The chinese pharmaceutical factory "borui biomedicine" also announced late tuesday night that they have succeeded in copying redsievert, in mass production.
Late tuesday night, chinese listed company borui biopharmaceutical (suzhou) co., ltd., announced that it had recently succeeded in copying "the synthetic technology and preparation technology of reedxiwei raw materials ".
Burry Bio stressed that the company had developed Redsievert in response to a national call to get early access to a treatment for pneumonia in Wuhan. If the product is allowed to go public, it will be mainly supplied to patients through donations during the epidemic period, and it is not expected to have a significant impact on the company`s performance in 2020.
Borrey admits that redsievere was developed by the american company gillia to suppress the ebola virus, which is the patentee of redsievere`s compound. The process will be "significant uncertainty" if reedsievert is to be marketed as a therapeutic drug.
In addition, mr redsievere has passed phase i and phase ii clinical trials abroad, and mr gilliya is now conducting phase iii clinical trials on his use in wuhan pneumonia. Follow-up (imitation, mass production) work will be carried out in a timely manner according to the needs of the country and society.
